October 13, 2023 (Investorideas.com Newswire) Despite recent positive clinical trials, the biopharma behind this treatment remains undervalued presenting a buying opportunity, noted an Oppenheimer report.
Soleno Therapeutics Inc.’s (SLNO:NASDAQ) investigative treatment for Prader-Willi syndrome, called DCCR (diazoxide choline), is expected to be approved, first in the States as early as next year, then later in the European Union, reported Oppenheimer analyst Dr. Leland Gershell in an October 10 research note. Prader-Willi is a rare genetic disorder in which hyperphagia, or the excessive desire to eat, “is the major source of morbidity and mortality.”
“Our attendance at the Foundation for Prader-Willi Research’s annual Research Symposium and Family Conference late last week reinforced our bullish view on DCCR’s U.S. Food and Drug Administration (FDA) approval and commercial prospects for Prader-Willi syndrome,” Gershell wrote.
Buying Opportunity, Attractive Return
As such, Oppenheimer reiterated its target price of US$39 per share on California-headquartered Soleno. Its current share price, in comparison, is about US$25.75 per share.
“We believe shares remain undervalued following the recent positive data,” wrote Gershell, referring to results of a Phase 3 study and a subsequent withdrawal trial. “We would continue to be buyers.”
The difference between the current and target prices implies a compelling return for investors of 51%.
Soleno remains rated as Outperform.
Expected Approval Dates
Oppenheimer expects the FDA to approve DCCR for Prader-Willi syndrome in the U.S. in 2024, with a commercial launch to follow by early 2025, Gershell wrote. Approval in the European Union (EU) is estimated to happen in 2026.
Further, Oppenheimer projects peak sales of DCCR to be US$1 billion or more in each region.
Takeaways From Meeting
Gershell pointed out that the clinicians Oppenheimer talked with at the conference indicated they were excited about the performance of DCCR in the recent randomized withdrawal trial. In it, the drug showed “a strongly significant benefit to hyperphagia,” thereby meeting the primary endpoint. Clinicians also indicated they did not have concerns about DCCR or it getting approved.
Some investors have expressed concern, noted Gershell, that study patients with a lower starting weight/BMI who stayed on DCCR may have “favored a drug effect.” However, while physicians at the conference acknowledged this was possible, they said it would not impact the hyperphagia endpoint.
More Info:
This news is published on the Investorideas.com Newswire – a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
That’s all it takes to get an article published on Investor Ideas – Learn More
